

[REDACTED]

From: O'Brien, Natasha [REDACTED]
Sent: Friday, 15 May 2020 11:56 AM
To: Dwyer, Ellie
Subject: Request for update: MTAA's application for authorisation AA1000479

Hello Ellie

Further to your correspondence dated 11 May 2020. I have left two voice mails however, I suspect that there may be some problem with your message bank as it cuts off and does not provide sufficient time to leave a number. Please see below for my number.

In respect of the questions in the correspondence, please see the following response from Roche Diagnostics Australia (RDA) a member of Pathology Technology Australia.

- Is the Proposed Conduct working as expected? N/A
- Is the Proposed Conduct taking place as described in the application and the interim authorisation decision? RDA has not engaged and/or undertaken any such conduct.
- Are there any particular benefits or detriments that the Proposed Conduct is resulting in? N/A
- Has your organisation engaged in the Proposed Conduct, and if so, what was your experience in doing so?
No
If not, why not? This has not been required.

Regards

Natasha O'Brien

Head of Legal and Compliance

Roche Diagnostics Australia Pty Ltd
2 Julius Avenue
North Ryde NSW 2113
Australia

Tel.: + [REDACTED]

Fax: + [REDACTED]

Email: [REDACTED]

Confidentiality Note: This message is intended only for the use of the named recipient(s) and may contain confidential and/or privileged information. If you are not the intended recipient, please contact the sender and delete this message. Any unauthorized use of the information contained in this message is prohibited.